Inactive Instrument
Cerevel Therapeutics Holdings, Inc. Stock
Stocks
CERE
US15678U1280
Biotechnology & Medical Research
| 1 day | +0.74% |
| 3 years | 21.86 |  | 44.99 |
| 5 years | 19.59 | | 46.16 |
| 10 years | 9 | | 46.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Renger
CTO | Chief Tech/Sci/R&D Officer | 57 | 2019-04-30 |
Matthew Calistri
IRC | Investor Relations Contact | - | - |
Paul Burgess
PRN | Corporate Officer/Principal | 53 | 2023-06-19 |
| Director | Title | Age | Since |
|---|---|---|---|
Deborah Baron
BRD | Director/Board Member | 57 | 2021-01-19 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 8/1/24 | Issuer sale | Chief Medical Officer | 1,495,399 | 0.8208% | ||
| 8/1/24 | Issuer sale | Director | 108,985 | 0.0598% | ||
| 8/1/24 | Issuer sale | Director | 137,525 | 0.0755% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.74% | -.--% | - | - | 8.19B | |
| +0.01% | +11.10% | +60.83% | +70.43% | 68.32B | |
| +0.83% | +6.92% | +14.27% | +89.39% | 60.26B | |
| +0.09% | -0.03% | +19.65% | +97.08% | 55.86B | |
| +1.60% | +19.44% | +28.80% | +112.95% | 48.43B | |
| -1.32% | +4.78% | +29.15% | +40.40% | 45.34B | |
| -3.54% | -0.60% | +207.76% | +879.50% | 41.76B | |
| -3.33% | +6.90% | +22.78% | +48.07% | 34.5B | |
| -1.09% | -1.40% | +83.85% | +56.24% | 33.8B | |
| -1.49% | +1.16% | +47.05% | +0.16% | 25.96B | |
| Average | -0.75% | +5.39% | +57.13% | +154.91% | 46B | |
| Weighted average by Cap. | -0.62% | +5.25% | +53.95% | +152.60% |
Employees
355
